1 EXECUTIVE SUMMARY 22

2 INTRODUCTION 28
2.1 KEY TAKEAWAYS 28
2.2 SCOPE OF THE REPORT 28
2.3 REPORT DESCRIPTION 29
2.4 MARKETS COVERED 32
2.5 STAKEHOLDERS 33
2.6 RESEARCH METHODOLOGY 34
2.6.1 MARKET SIZE ESTIMATION 35
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 38
2.6.3 SECONDARY SOURCES 39
2.6.4 PRIMARY SOURCES 40
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 40
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 41
2.6.7 ASSUMPTIONS 41

3 MARKET ANALYSIS 44
3.1 INTRODUCTION 44
3.2 MARKET SEGMENTATION 45
3.3 FACTORS INFLUENCING MARKET 47
3.3.1 DRIVERS AND OPPORTUNITY 47
3.3.1.1 Rising incidence of cancer and old age population 47
3.3.1.2 Increase in technological advancement in cancer diagnostics 48
3.3.1.3 Increase in healthcare expenditure 50
3.3.1.4 Infrastructure and investments by government and private companies 50
3.3.1.5 emerging markets and increasing awareness of various cancers 51
3.3.1.6 Personalized medicine 52
3.3.1.7 Mandatory early screening 53
3.3.2 RESTRAINTS AND THREATS 54
3.3.2.1 High cost of advanced technologies 54
3.3.2.2 Lack of skilled professionals hampering the growth of cancer diagnostics market 55
3.3.2.3 Product recall due to manufacturing and quality issues 56
3.3.2.4 Stringent regulations 57
3.3.2.5 Lack of reimbursement 58
3.4 MARKET SHARE ANALYSIS 59
3.4.1 CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS 59
3.5 REGULATORY AFFAIRS 64
3.5.1 U.S. 66
3.5.2 EUROPE 66
3.5.3 CHINA 68
3.5.4 INDIA 69
3.5.5 JAPAN 70
3.5.6 AUSTRALIA 70
3.5.7 SOUTH KOREA 71
3.6 REIMBURSEMENT SCENARIO 72
3.7 CLINICAL TRIALS 73
3.7.1 CTDNA CLINICALTRIALS 73
3.7.2 CFDNA CLINICALTRIALS 74
3.7.3 CIRCULATING TUMOR CELLS 75
3.7.4 COMPANION DIAGNOSTICS 76
3.7.5 IMMUNOASSAYS 78
3.8 PORTER'S FIVE FORCE ANALYSIS 78
3.8.1 THREAT OF NEW ENTRANTS 79
3.8.2 THREAT OF SUBSTITUTES 80
3.8.3 COMPETITIVE RIVALRY 80
3.8.4 BARGAINING POWER OF SUPPLIERS 81
3.8.5 BARGAINING POWER OF BUYERS 82

4 CANCER DIAGNOSTICS PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM) 83
4.1 RESEARCH METHODOLOGY 83
4.2 FORECAST METHODOLOGY 83
4.3 NORTH AMERICA CANCER DIAGNOSIS ADDRESSABLE MARKET 83
4.3.1 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM) 83
4.3.1.1 Early Screening: 83
4.3.1.2 U.S. colorectal cancer diagnosis, companion diagnostics, prognosis and
recurrence monitoring total addressable market (TAM) 84
4.3.2 U.S. BREAST CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM) 86
4.3.2.1 Early Screening 86
4.3.2.2 U.S. breast cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM): 87
4.3.3 U.S. PROSTATE CANCER DIAGNOSTICS TOTAL ADDRESSABLE
MARKET (TAM) 88
4.3.3.1 Early Screening: 88
4.3.3.2 U.S. prostate cancer diagnosis, companion diagnostics, prognosis and
recurrence monitoring total addressable market (TAM) 89
4.3.4 U.S. LUNG CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM) 91
4.3.4.1 Early Screening: 91
4.3.4.2 U.S. lung cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (tam): 92
4.3.5 U.S. OTHER CANCER DIAGNOSIS, COMPANION DIAGNOSTICS,
PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE
MARKET (TAM) 93
4.3.6 REST OF N.A. CANCER DIAGNOSIS, COMPANION DIAGNOSTICS,
PROGNOSIS AND RECURRENCE MONITORING TOTAL
ADDRESSABLE MARKET (TAM) 94
4.4 EUROPE CANCER DIAGNOSIS ADDRESSABLE MARKET 95
4.4.1 EUROPE CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS
AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM) 95
4.5 APAC CANCER DIAGNOSIS ADDRESSABLE MARKET 97
4.5.1 APAC CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS
AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM) 97
4.6 ROW CANCER DIAGNOSIS ADDRESSABLE MARKET 98
4.6.1 ROW CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM) 98
4.7 CANCER CARE GLOBAL ADDRESSABLE MARKET 99
4.7.1 EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKET
BY CANCER TYPE AND BY REGION 99
4.7.2 PROGNOSIS MONITORING GLOBAL TOTAL ADDRESSABLE MARKET
BY REGION 101
4.7.3 COMPANION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET
BY REGION 102
4.7.4 RECURRENCE MONITORING GLOBAL TOTAL ADDRESSABLE MARKET
BY REGION 103

5 CANCER DIANOSTICS GLOBAL MARKET, BY TECHNOLOGY 104
5.1 INTRODUCTION 104
5.2 IMMUNOASSAYS 106
5.2.1 IMMUNOHISTOCHEMISTRY (IHC) 109
5.2.2 ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA) 111
5.3.3 OTHER IMMUNOASSAYS 112
5.4 MOLECULAR BASED ASSAYS 118
5.4.1 IN-SITU HYBRIDIZATION 121
5.4.2 POLYMERASE CHAIN REACTION (PCR) 123
5.4.3 MICROARRAY 125
5.4.4 SEQUENCING 126
5.5 OTHERS 128

6 CANCER DIAGNOSTICS GLOBAL MARKET, BY SAMPLE SOURCE 130
6.1 INTRODUCTION 130
6.2 BLOOD 132
6.3 TISSUE 135
6.4 OTHERS 137

7 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER TYPE 141
7.1 INTRODUCTION 141
7.2 CANCER TYPES 143
7.2.1 LUNG CANCER 144
7.2.2 BREAST CANCER 146
7.2.3 COLORECTAL CANCER 148
7.2.4 PROSTATE CANCER 149
7.2.5 LIVER CANCER 151
7.2.6 OVARIAN CANCER 152
7.2.7 OTHERS 154

8 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET,
BY CANCER CARE 158
8.1 INTRODUCTION 158
8.2 DIAGNOSIS 161
8.3 EARLY SCREENING 163
8.4 COMPANION DIAGNOSIS 165
8.5 PROGNOSIS 167
8.6 RECURRENCE MONITORING 169

9 CANCER DIAGNOSTICS GLOBAL MARKET, BY END-USERS 171
9.1 INTRODUCTION 171
9.2 HOSPITALS 174
9.3 CLINICAL/CENTRALIZED LABORATORIES 176
9.4 OTHERS 178

10 CANCER DIAGNOSTICS GLOBAL MARKET BY REGION 181
10.1 INTRODUCTION 181
10.2 NORTH AMERICA 185
10.2.1 U.S. 201
10.2.2 REST OF NORTH AMERICA 206
10.3 EUROPE 211
10.3.1 GERMANY 228
10.3.2 FRANCE 232
10.3.3 UNITED KINGDOM 236
10.3.4 REST OF EUROPE 240
10.4 ASIA-PACIFIC 245
10.4.1 JAPAN 261
10.4.2 CHINA 266
10.4.3 INDIA 270
10.4.4 REST OF ASIA-PACIFIC 275
10.5 REST OF THE WORLD 279
10.5.1 BRAZIL 296
10.5.2 REST OF LATIN AMERICA 300
10.5.3 MIDDLE EAST AND OTHER COUNTRIES 304

11 COMPETITIVE LANDSCAPE 309
11.1 INTRODUCTION 309
11.2 APPROVALS 310
11.3 COLLABORATION 316
11.4 NEW PRODUCT LAUNCHES 319
11.5 ACQUSTIONS 321
11.6 OTHERS 323

12 MAJOR COMPANIES 328
12.1 ABBOTT LABORATORIES 328
12.1.1 OVERVIEW 328
12.1.2 FINANCIALS 329
12.1.3 PRODUCT PORTFOLIO 332
12.1.4 KEY DEVELOPMENTS 332
12.1.5 BUSINESS STRATEGY 332
12.1.6 SWOT ANALYSIS 333
12.2 AGILENT TECHNOLOGIES, INC 334
12.2.1 OVERVIEW 334
12.2.2 FINANCIALS 335
12.2.3 PRODUCT PORTFOLIO 336
12.2.4 KEY DEVELOPMENTS 337
12.2.5 BUSINESS STRATEGY 339
12.2.6 SWOT ANALYSIS 340
12.3 DANAHER CORPORATION 341
12.3.1 OVERVIEW 341
12.3.2 FINANCIALS 342
12.3.3 PRODUCT PORTFOLIO 344
12.3.4 KEY DEVELOPMENTS 345
12.3.5 BUSINESS STRATEGY 345
12.3.6 SWOT ANALYSIS 346
12.4 EXACT SCIENCES CORPORATION 347
12.4.1 OVERVIEW 347
12.4.2 FINANCIALS 348
12.4.3 PRODUCT PORTFOLIO 350
12.4.4 KEY DEVELOPMENTS 350
12.4.5 BUSINESS STRATEGY 352
12.4.6 SWOT ANALYSIS 353
12.5 GUARDANT HEALTH, INC. 354
12.5.1 OVERVIEW 354
12.5.2 FINANCIALS 355
12.5.3 PRODUCT PORTFOLIO 357
12.5.4 KEY DEVELOPMENTS 357
12.5.5 BUSINESS STRATEGY 359
12.5.6 SWOT ANALYSIS 360
12.6 HOLOGIC, INC. 361
12.6.1 OVERVIEW 361
12.6.2 FINANCIALS 362
12.6.3 PRODUCT PORTFOLIO 365
12.6.4 KEY DEVELOPMENTS 365
12.6.5 BUSINESS STRATEGY 366
12.6.6 SWOT ANALYSIS 366
12.7 MYRIAD GENETICS, INC. 367
12.7.1 OVERVIEW 367
12.7.2 FINANCIALS 368
12.7.3 PRODUCT PORTFOLIO 371
12.7.4 KEY DEVELOPMENTS 371
12.7.5 BUSINESS STRATEGY 376
12.7.6 SWOT ANALYSIS 377
12.8 QIAGEN N.V. 378
12.8.1 OVERVIEW 378
12.8.2 FINANCIALS 379
12.8.3 PRODUCT PORTFOLIO 382
12.8.4 KEY DEVELOPMENTS 384
12.8.5 BUSINESS STRATEGY 386
12.8.6 SWOT ANALYSIS 388
12.9 ROCHE 389
12.9.1 OVERVIEW 389
12.9.2 FINANCIALS 390
12.9.3 PRODUCT PORTFOLIO 393
12.9.4 KEY DEVELOPMENTS 394
12.9.5 BUSINESS STRATEGY 397
12.9.6 SWOT ANALYSIS 398
12.10 SIEMENS HEALTHINEERS 399
12.10.1 OVERVIEW 399
12.10.2 FINANCIALS 400
12.10.3 PRODUCT PORTFOLIO 402
12.10.4 KEY DEVELOPMENTS 403
12.10.5 BUSINESS STRATEGY 403
12.10.6 SWOT ANALYSIS 404

LIST OF TABLES
TABLE 1 CANCER DIANGOSTICS GLOBAL MARKET REVENUE, BY REGION,
(2018-2026) ($MN) 26
TABLE 2 EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKET, BY CANCER TYPE VS REGION (2019) ($MN) 99
TABLE 3 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY
(2018-2026) ($MN) 105
TABLE 4 IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 107
TABLE 5 IMMUNOASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY
(2018-2026) ($MN) 108
TABLE 6 IMMUNOHISTOCHEMISTRY (IHC) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 110
TABLE 7 ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 112
TABLE 8 OTHER IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 118
TABLE 9 MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN) 119
TABLE 10 MOLECULAR BASED ASSAYS GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 121
TABLE 11 IN-SITU HYBRIDIZATION (ISH) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 122
TABLE 12 POLYMERASE CHAIN REACTION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 124
TABLE 13 MICROARRAYS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 126
TABLE 14 SEQUENCING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 127
TABLE 15 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 129
TABLE 16 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN) 131
TABLE 17 BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 134
TABLE 18 TISSUE SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 136
TABLE 19 OTHER SAMPLE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 140
TABLE 20 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE,
BY CANCER TYPE (2018-2026) ($MN) 142
TABLE 21 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 146
TABLE 22 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 147
TABLE 23 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 149
TABLE 24 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 150
TABLE 25 LIVER CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 151
TABLE 26 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 153
TABLE 27 OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 157
TABLE 28 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET REVENUE,
BY CANCER CARE (2018-2026) ($MN) 159
TABLE 29 DIAGNOSIS GLOBAL MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN) 162
TABLE 30 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 164
TABLE 31 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 166
TABLE 32 PROGNOSIS MONITORING GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 168
TABLE 33 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 170
TABLE 34 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS
(2018-2026) ($MN) 172
TABLE 35 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 175
TABLE 36 CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE,
BY REGION (2018-2026) ($MN) 177
TABLE 37 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN) 180
TABLE 38 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 182
TABLE 39 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE,
BY TECHNOLOGY (2018-2026) ($MN) 186
TABLE 40 NORTH AMERICA IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN) 188
TABLE 41 NORTH AMERICA MOLECULAR BASED ASSAYS MARKET REVENUE,
BY TECHNOLOGY (2018-2026) ($MN) 190
TABLE 42 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN) 192
TABLE 43 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2018-2026) ($MN) 194
TABLE 44 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER CARE (2018-2026) ($MN) 196
TABLE 45 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN) 198
TABLE 46 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN) 200
TABLE 47 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2018-2026) ($MN) 212
TABLE 48 EUROPE IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY
(2018-2026) ($MN) 214
TABLE 49 EUROPE MOLECULAR BASED ASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN) 216
TABLE 50 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN) 218
TABLE 51 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2018-2026) ($MN) 220
TABLE 52 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER CARE (2018-2026) ($MN) 222
TABLE 53 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER
(2018-2026) ($MN) 224
TABLE 54 EUROPE CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY
(2018-2026) ($MN) 226
TABLE 55 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN) 246
TABLE 56 ASIA-PACIFIC IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY
(2018-2026) ($MN) 248
TABLE 57 ASIA-PACIFIC MOLECULAR BASED ASSAYS MARKET REVENUE,
BY TECHNOLOGY (2018-2026) ($MN) 250
TABLE 58 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN) 252
TABLE 59 ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2018-2026) ($MN) 254
TABLE 60 ASIA-PACIFIC CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER CARE (2018-2026) ($MN) 256
TABLE 61 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY END-USER (2018-2026) ($MN) 258
TABLE 62 ASIA-PACIFIC CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN) 260
TABLE 63 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE,
BY TECHNOLOGY (2018-2026) ($MN) 280
TABLE 64 REST OF THE WORLD IMMUNOASSAYS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN) 282
TABLE 65 REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET REVENUE,
BY TECHNOLOGY (2018-2026) ($MN) 284
TABLE 66 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY SAMPLE SOURCE (2018-2026) ($MN) 286
TABLE 67 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN) 288
TABLE 68 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN) 290
TABLE 69 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE,
BY END-USER (2018-2026) ($MN) 292
TABLE 70 REST OF THE WORLD CANCER DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN) 294
TABLE 71 APPROVALS (2018-2020) 311
TABLE 72 COLLABORATIONS (2018-2020) 317
TABLE 73 NEW PRODUCT LAUNCH (2018-2020) 319
TABLE 74 ACQUISITIONS (2016-2018) 321
TABLE 75 OTHERS (2018-2020) 323
TABLE 76 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES,
(2017-2019) ($MN) 329
TABLE 77 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS
(2017-2019) ($MN) 330
TABLE 78 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY
(2017-2019) ($MN) 331
TABLE 79 AGILENT TECHNOLOGIES, INC: TOTAL REVENUE AND R&D EXPENSES,
(2017-2019) ($MN) 335
TABLE 80 AGILENT TECHNOLOGIES, INC: TOTAL REVENUE, BY SEGMENTS
(2017-2019) ($MN) 336
TABLE 81 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES,
(2017-2019) ($MN) 342
TABLE 82 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT,
(2017-2019) ($MN) 343
TABLE 83 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,
(2017-2019) ($MN) 344
TABLE 84 EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN) 348
TABLE 85 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY SEGMENT
(2017-2019) ($MN) 349
TABLE 86 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY
(2017-2019) ($MN) 349
TABLE 87 GUARDANT HEALTH, INC: TOTAL REVENUE AND R&D EXPENSES,
(2017-2019) ($MN) 355
TABLE 88 GUARDANT HEALTH, INC: TOTAL REVENUE, BY SEGMENT,
(2017-2019) ($MN) 356
TABLE 89 GUARDANT HEALTH, INC: TOTAL REVENUE, BY GEOGRAPHY,
(2017-2019) ($MN) 356
TABLE 90 HOLOGIC, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN) 362
TABLE 91 HOLOGIC, INC.: TOTAL REVENUE, BY PRODUCT SEGMENT,
(2017-2019) ($MN) 363
TABLE 92 HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN) 364
TABLE 93 MYRIAD GENETICS, INC : TOTAL REVENUE AND R&D EXPENSES,
(2017-2019) (Q2) ($MN) 368
TABLE 94 MYRIAD GENETICS: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q2) ($MN) 369
TABLE 95 MYRIAD GENETICS:DIAGNOSTICS AND OTHERS BY PRODUCT SEGMENT, (2017-2019) (Q2) ($MN) 370
TABLE 96 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN) 379
TABLE 97 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN) 380
TABLE 98 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN) 381
TABLE 99 ROCHE: TOTAL REVENUE AND R&D EXPENSES,
(2017-2019) (Q3) ($MN) 390
TABLE 100 ROCHE: TOTAL REVENUE, BY SEGMENTS,
(2017-2019) (Q3) ($MN) 391
TABLE 101 ROCHE: TOTAL REVENUE, BY DIAGNOSTICS SUB-SEGMENTS, (2017-2019) (Q3) ($MN) 392
TABLE 102 ROCHE: TOTAL DIAGNOSTIC REVENUE, BY REGIONS, (2017-2019) (Q3) ($MN) 393
TABLE 103 SIEMENS HEALTHINEERS : TOTAL REVENUE AND R&D EXPENSES,
(2017-2019) ($MN) 400
TABLE 104 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY SEGMENT (2017-2019) ($MN) 401
TABLE 105 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY GEOGRAPHY
(2017-2019) ($MN) 402

LIST OF FIGURES

FIGURE 1 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 27
FIGURE 2 RESEARCH METHODOLOGY: CANCER DIAGNOSTICS GLOBAL MARKET 35
FIGURE 3 CANCER DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 36
FIGURE 4 CANCER DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL 37
FIGURE 5 CANCER DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION 38
FIGURE 6 CANCER DIAGNOSTICS GLOBAL MARKET SEGMENTATION 46
FIGURE 7 MARKET DYNAMICS 47
FIGURE 8 CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019) (%) 59
FIGURE 9 CANCER DIAGNOTICS GLOBAL MARKET: PORTER'S ANALYSIS 79
FIGURE 10 U.S. COLORECTAL CANCER EARLY SCREENING PENETRATION AND TOTAL ADDRESSABLE MARKET (%) ($ MN) 84
FIGURE 11 U.S. COLORECTAL CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TAM ($MN) 85
FIGURE 12 U.S. COLORECTAL CANCER EARLY SCREENING MARKET SHARE,
BY PLAYERS (%) 86
FIGURE 13 U.S. BREAST CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET
($ MN) 87
FIGURE 14 U.S. BREAST CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN) 88
FIGURE 15 U.S. PROSTATE CANCER EARLY SCREENING TOTAL ADDRESSABLE
MARKET ($ MN) 89
FIGURE 16 U.S. PROSTATE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE
MARKET ($MN) 90
FIGURE 17 U.S. LUNG CANCER EARLY SCREENING TOTAL ADDRESSABLE MARKET ($ MN) 91
FIGURE 18 U.S. LUNG CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN) 93
FIGURE 19 U.S. OTHER CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN) 94
FIGURE 20 REST OF N.A. CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN) 95
FIGURE 21 EUROPE CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN) 96
FIGURE 22 APAC CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN) 97
FIGURE 23 ROW CANCER DIAGNOSIS, PROGNOSIS,COMPANION DIAGNOSTICS, RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET ($MN) 98
FIGURE 24 COLORECTAL CANCER EARLY SCREENING GLOBAL TAM, BY REGION,
2019 ($MN) 99
FIGURE 25 PROSTATE CANCER EARLY SCREENING GLOBAL TAM, BY REGION,
2019 ($MN) 100
FIGURE 26 BREAST CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN) 100
FIGURE 27 LUNG CANCER EARLY SCREENING GLOBAL TAM, BY REGION, 2019 ($MN) 101
FIGURE 28 PROGNOSIS MONITORING GLOBAL TAM, BY REGION, 2019 ($MN) 101
FIGURE 29 COMPANION DIAGNOSTICS GLOBAL TAM, BY REGION, 2019 ($MN) 102
FIGURE 30 RECURRENCE MONITORING GLOBAL TAM, BY REGION, 2019 ($MN) 103
FIGURE 31 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 106
FIGURE 32 IMMUNOASSAY GLOBAL MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 109
FIGURE 33 MOLECULAR BASED ASSAYS GLOBAL MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%) 120
FIGURE 34 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY SAMPLE SOURCE
(2019 VS 2026) (%) 132
FIGURE 35 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET SHARE, BY CANCER TYPE (2019 VS 2026) (%) 143
FIGURE 36 GLOBAL CANCER PREVALENCE AND INCIDENCE RATE BY TYPE (2019) (%) 144
FIGURE 37 CANCER DIAGNOSTICS APPLICAION GLOBAL MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%) 160
FIGURE 38 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USERS
(2019 VS 2026) (%) 173
FIGURE 39 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION
(2018-2026) ($MN) 183
FIGURE 40 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, MARKET REVENUE BY COUNTRY (2019) (%) ($MN) 184
FIGURE 41 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%) 187
FIGURE 42 NORTH AMERICA IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 189
FIGURE 43 NORTH AMERICA MOLECULAR BASED ASSAYS MARKET SHARE,
BY TECHNOLOGY (2019 VS 2026) (%) 191
FIGURE 44 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%) 193
FIGURE 45 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE,
BY CANCER TYPE (2019 VS 2026) (%) 195
FIGURE 46 NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET SHARE,
BY CANCER CARE (2019 VS 2026) (%) 197
FIGURE 47 NORTH AMERICA CANCER DIAGNOSTICS L MARKET SHARE, BY END-USER (2019 VS 2026) (%) 199
FIGURE 48 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%) 201
FIGURE 49 U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 203
FIGURE 50 U.S. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN) 204
FIGURE 51 U.S. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND
END-USERS (2019 VS 2026) ($MN) 205
FIGURE 52 REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE,
BY TECHNOLOGY (2019 VS 2026) ($MN) 208
FIGURE 53 REST OF NORTH AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN) 209
FIGURE 54 REST OF NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE,
BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 210
FIGURE 55 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 213
FIGURE 56 EUROPE IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 215
FIGURE 57 EUROPE MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%) 217
FIGURE 58 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE
(2019 VS 2026) (%) 219
FIGURE 59 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE,
BY CANCER CARE (2019 VS 2026) (%) 221
FIGURE 60 EUROPE CANCER DIAGNOSTICS APPLICATION MARKET SHARE,
BY CANCER CARE (2019 VS 2026) (%) 223
FIGURE 61 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY END-USER
(2019 VS 2026) (%) 225
FIGURE 62 EUROPE CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY
(2019 VS 2026) (%) 227
FIGURE 63 GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 229
FIGURE 64 GERMANY CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2019) ($MN) 230
FIGURE 65 GERMANY CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 231
FIGURE 66 FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 233
FIGURE 67 FRANCE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2019) ($MN) 234
FIGURE 68 FRANCE CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 235
FIGURE 69 U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 237
FIGURE 70 U.K. CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN) 238
FIGURE 71 U.K. CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND
END-USERS (2019 VS 2026) ($MN) 239
FIGURE 72 REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE,
BY TECHNOLOGY (2019 VS 2026) ($MN) 242
FIGURE 73 REST OF EUROPE CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN) 243
FIGURE 74 REST OF EUROPE CANCER DIAGNOSTICS MARKET REVENUE,
BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 244
FIGURE 75 APAC CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 247
FIGURE 76 APAC IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 249
FIGURE 77 APAC MOLECULAR BASED ASSAYS MARKET SHARE, BY TECHNOLOGY
(2019 VS 2026) (%) 251
FIGURE 78 APAC CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE
(2019 VS 2026) (%) 253
FIGURE 79 APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE,
BY CANCER CARE (2019 VS 2026) (%) 255
FIGURE 80 APAC CANCER DIAGNOSTICS APPLICATION MARKET SHARE,
BY CANCER CARE (2019 VS 2026) (%) 257
FIGURE 81 APAC CANCER DIAGNOSTICS MARKET SHARE, BY END-USER
(2019 VS 2026) (%) 259
FIGURE 82 APAC CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY
(2019 VS 2026) (%) 261
FIGURE 83 JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 263
FIGURE 84 JAPAN CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2019) ($MN) 264
FIGURE 85 JAPAN CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 265
FIGURE 86 CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 267
FIGURE 87 CHINA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2019) ($MN) 268
FIGURE 88 CHINA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE
AND END-USERS (2019 VS 2026) ($MN) 269
FIGURE 89 INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 272
FIGURE 90 INDIA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2019) ($MN) 273
FIGURE 91 INDIA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 274
FIGURE 92 REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 VS 2026) ($MN) 276
FIGURE 93 REST OF APACCANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2019) ($MN) 277
FIGURE 94 REST OF APAC CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 278
FIGURE 95 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE,
BY TECHNOLOGY (2019 VS 2026) (%) 281
FIGURE 96 REST OF THE WORLD IMMUNOASSAYS MARKET SHARE, BY TECHNOLOGY (2019 VS 2026) (%) 283
FIGURE 97 REST OF THE WORLD MOLECULAR BASED ASSAYS MARKET SHARE,
BY TECHNOLOGY (2019 VS 2026) (%) 285
FIGURE 98 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY SAMPLE SOURCE (2019 VS 2026) (%) 287
FIGURE 99 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%) 289
FIGURE 100 REST OF THE WORLD CANCER DIAGNOSTICS APPLICATION MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%) 291
FIGURE 101 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY END-USER (2019 VS 2026) (%) 293
FIGURE 102 REST OF THE WORLD CANCER DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 VS 2026) (%) 295
FIGURE 103 BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY
(2019 VS 2026) ($MN) 297
FIGURE 104 BRAZIL CANCER DIAGNOSTICS APPLICATION MARKET REVENUE,
BY CANCER TYPE (2019) ($MN) 298
FIGURE 105 BRAZIL CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 299
FIGURE 106 REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE,
BY TECHNOLOGY (2019 VS 2026) ($MN) 301
FIGURE 107 REST OF LATIN AMERICA CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN) 302
FIGURE 108 REST OF LATIN AMERICA CANCER DIAGNOSTICS MARKET REVENUE,
BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 303
FIGURE 109 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE,
BY TECHNOLOGY (2019 VS 2026) ($MN) 306
FIGURE 110 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS APPLICATION MARKET REVENUE, BY CANCER TYPE (2019) ($MN) 307
FIGURE 111 MIDDLE EAST AND OTHERS CANCER DIAGNOSTICS MARKET REVENUE,
BY CANCER CARE AND END-USERS (2019 VS 2026) ($MN) 308
FIGURE 112 KEY GROWTH STRATEGIES, (2018 - 2020) 310
FIGURE 113 SWOT: ABBOTT LABORATORIES 333
FIGURE 114 SWOT: AGILENT TECHNOLOGIES 340
FIGURE 115 SWOT: DANAHER CORPORATION 346
FIGURE 116 SWOT: EXACT SCIENCES 353
FIGURE 117 SWOT: GUARDANT HEALTH 360
FIGURE 118 SWOT: HOLOGIC INC. 366
FIGURE 119 SWOT: MYRIAD GENETICS 377
FIGURE 120 SWOT: QIAGEN N.V. 388
FIGURE 121 SWOT: ROCHE 398
FIGURE 122 SWOT: SIEMENS HEALTHINEERS 404

Companies Mentioned
• ABBOTT LABORATORIES
• AGILENT TECHNOLOGIES
• DANAHER CORPORATION
• EXACT SCIENCES
• GUARDANT HEALTH
• HOLOGIC INC.
• MYRIAD GENETICS
• QIAGEN N.V.
• ROCHE
• SIEMENS HEALTHINEERS
• LIST OF COMPANIES MENTIONED IN THE REPORT
• ABBOTT LABORATORIES
• ACCURAGEN, INC
• ACRANNOLIFE GENOMICS
• ADAPTIVE BIOTECHNOLOGIES
• AGENA BIOSCIENCES
• AGENDIA
• AGILENT TECHNOLOGIES
• ANGLE PLC
• ANGSANA MOLECULAR & DIAGNOSTIC LABORATORY (AMDL) PTE LTD.
• ARUP LABORATORIES
• AVANT DIAGNOSTICS
• BARD1 LIFE SCIENCES LTD
• BGI
• BIOAFFINITY TECHNOLOGIES
• BIOARRAY SL
• BIOCARTIS
• BIOCEPT
• BIODESIX, INC
• BIOGENEX
• BIOMARK DIAGNOSTICS, INC
• BIOMÉRIEUX
• BIO-RAD LABORATORIES
• BIORELIANCE
• BIO-TECHNE CORPORATION
• BIOTHERANOSTICS
• BIOTYPE DIAGNOSTIC GMBH
• BIOVICA
• BOSTER BIOLOGICAL TECHNOLOGY
• CANCER GENETICS, INC
• CANCER TREATMENT OPTIONS AND MANAGEMENT INC
• CARIS LIFESCIENCES
• CASTLE BIOSCIENCES
• CELL MAX LIFE
• CELL SIGNALING TECHNOLOGY
• CHRONIX BIOMEDICAL
• CIRCULOGENE
• CLEVELAND DIAGNOSTICS
• CLINICAL GENOMICS TECHNOLOGIES PTY LTD
• CONCILE GMBH
• CONTEXTUAL GENOMICS
• CREATIVE DIAGNOSTICS
• DAKO NORTH AMERICA, INC
• DANAHER CORPORATION
• DATAR CANCER DIAGNOSTICS
• DELTAGENE
• DIACARTA
• DIASORIN
• DIASOURCE IMMUNOASSAYS SA
• ELABSCIENCE
• ENTERIX, INC
• ENZO LIFESCIENCES
• EPIGENOMICS GMBH
• EPPENDORF AG
• EXACT SCIENCES CORPORATION
• EXOSOME DIAGNOSTICS, INC
• EXOSOMICS S.P.A
• F. HOFFMANN-LA ROCHE LTD
• FARCAST BIOSCIENCES, INC
• FOUNDATION MEDICINE
• GENE EDITING INSTITUTE AT CHRISTIANA CARE HEALTH SYSTEM
• GENERAL BIOLOGICALS CORPORATION
• GENOMA GROUP
• GENOMEME
• GENOMIC DIAGNOSTICS
• GENOMIC VISION
• GENOPTIX
• GUARDANT HEALTH
• HALIODX
• HEMOSURE, INC
• HOLOGIC,INC
• ICON, PLC
• IKONISYS
• IMMUNOSTICS
• INDIVUMED GMBH
• INIVATA
• INOVA DIAGNOSTICS
• INTEGRATED DIAGNOSTICS, INC
• INVIVOSCRIBE TECHNOLOGIES, INC.
• JOHNSON & JOHNSON (JANSSEN DIAGNOSTICS)
• LABCORP
• LCM GENECT SRL
• LIFESPAN BIOSCIENCES
• LIQUID BIOTECH USA
• LUMINEX CORPORATION
• LUNGLIFE AI
• LXREPAIR
• MAPMYGENOME INDIA LTD
• MDXHEALTH
• MEDGENOME LABS LTD.
• MENARINI SILICON BIOSYSTEMS
• MERCK KGAA
• METAMARK GENETICS, INC
• MICHELSON DIAGNOSTICS
• MIRDETECT GMBH
• MIRXES PTE LTD
• MYBIOSOURCE
• MYRIAD GENETICS
• NANOSTRING TECHNOLOGIES
• NATERA
• NEO NEW ONCOLOGY GMBH
• NEOGENOMICS LABORATORIES
• NOVIGENIX
• ONCGNOSTICS GMBH
• ONCIMMUNE
• ONCOCYTE CORPORATION
• ONCODIAG
• OPKO HEALTH INC
• OXFORD CANCER BIOMARKER
• OXFORD GENE TECHNOLOGY
• PANAGENE
• PANGAEA ONCOLOGY
• PATHWAY GENOMICS
• PERKINELMER INC.
• PERSONAL GENOME DIAGNOSTICS, INC
• PRECIPIODX
• PREDICINE, INC
• QIAGEN N.V
• QUIDEL CORPORATION, U.S.
• R&D SYSTEMS, INC,
• RESOLUTION BIOSCIENCE
• RHYTHM BIOSCIENCES
• RIBOMED
• SANSURE BIOTECH
• SIEMENS HEALTHINEERS
• SIENNA CANCER DIAGNOSTICS
• SINO BIOLOGICAL INC.
• SPHINGOTEC GMBH
• STAGE ZERO LIFE SCIENCES
• SYNLAB INTERNATIONAL GMBH
• SYSMEX CORPORATION
• THERADIAG
• THERMOFISHER SCIENTIFIC
• THRIVE EARLIER DETECTION
• TOSOH BIOSCIENCES
• VIENNALAB DIAGNOSTICS GMBH